Straits Times Index
3,267.54 +8.40 (+0.26%) S&P 500
3,998.84 -72.86 (-1.79%) Dow
33,947.10 -482.78 (-1.40%) Nasdaq
11,239.94 -221.56 (-1.93%) BTC-USD
17,026.52 -207.56 (-1.20%) CMC Crypto 200
402.37 -8.84 (-2.15%)
Precision BioSciences, Inc. (DTIL)
After hours:
| Previous close | 1.3400 |
| Open | 1.3400 |
| Bid | 1.2300 x 21500 |
| Ask | 1.2900 x 3000 |
| Day's range | 1.2300 - 1.3400 |
| 52-week range | 1.1100 - 9.4100 |
| Volume | |
| Avg. volume | 684,933 |
| Market cap | 137.589M |
| Beta (5Y monthly) | 1.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6700 |
| Earnings date | 08 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.33 |
- Business Wire
Precision BioSciences Announces Change to its Board of Directors
DURHAM, N.C., November 10, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Dr. Raymond Schinazi is stepping down from the company’s Board of Directors and will continue as a member of the company’s SAB, lending his deep expertise in antiviral drug discovery and development.
- Zacks
Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 37.14% and 37.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
DURHAM, N.C., November 08, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.
